Calcification of the thoracic aorta on low-dose chest CT predicts severe COVID-19.
Adult
Aorta, Thoracic
/ diagnostic imaging
COVID-19
/ diagnosis
Critical Care
Female
Hospitalization
Humans
Intubation, Intratracheal
/ methods
Lung
/ diagnostic imaging
Male
Middle Aged
Patient Admission
Radiation Dosage
SARS-CoV-2
/ pathogenicity
Thorax
/ diagnostic imaging
Tomography, X-Ray Computed
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
08
2020
accepted:
08
12
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Cardiovascular comorbidity anticipates poor prognosis of SARS-CoV-2 disease (COVID-19) and correlates with the systemic atherosclerotic transformation of the arterial vessels. The amount of aortic wall calcification (AWC) can be estimated on low-dose chest CT. We suggest quantification of AWC on the low-dose chest CT, which is initially performed for the diagnosis of COVID-19, to screen for patients at risk of severe COVID-19. Seventy consecutive patients (46 in center 1, 24 in center 2) with parallel low-dose chest CT and positive RT-PCR for SARS-CoV-2 were included in our multi-center, multi-vendor study. The outcome was rated moderate (no hospitalization, hospitalization) and severe (ICU, tracheal intubation, death), the latter implying a requirement for intensive care treatment. The amount of AWC was quantified with the CT vendor's software. Of 70 included patients, 38 developed a moderate, and 32 a severe COVID-19. The average volume of AWC was significantly higher throughout the subgroup with severe COVID-19, when compared to moderate cases (771.7 mm3 (Q1 = 49.8 mm3, Q3 = 3065.5 mm3) vs. 0 mm3 (Q1 = 0 mm3, Q3 = 57.3 mm3)). Within multivariate regression analysis, including AWC, patient age and sex, as well as a cardiovascular comorbidity score, the volume of AWC was the only significant regressor for severe COVID-19 (p = 0.004). For AWC > 3000 mm3, the logistic regression predicts risk for a severe progression of 0.78. If there are no visually detectable AWC risk for severe progression is 0.13, only. AWC seems to be an independent biomarker for the prediction of severe progression and intensive care treatment of COVID-19 already at the time of patient admission to the hospital; verification in a larger multi-center, multi-vendor study is desired.
Sections du résumé
BACKGROUND
Cardiovascular comorbidity anticipates poor prognosis of SARS-CoV-2 disease (COVID-19) and correlates with the systemic atherosclerotic transformation of the arterial vessels. The amount of aortic wall calcification (AWC) can be estimated on low-dose chest CT. We suggest quantification of AWC on the low-dose chest CT, which is initially performed for the diagnosis of COVID-19, to screen for patients at risk of severe COVID-19.
METHODS
Seventy consecutive patients (46 in center 1, 24 in center 2) with parallel low-dose chest CT and positive RT-PCR for SARS-CoV-2 were included in our multi-center, multi-vendor study. The outcome was rated moderate (no hospitalization, hospitalization) and severe (ICU, tracheal intubation, death), the latter implying a requirement for intensive care treatment. The amount of AWC was quantified with the CT vendor's software.
RESULTS
Of 70 included patients, 38 developed a moderate, and 32 a severe COVID-19. The average volume of AWC was significantly higher throughout the subgroup with severe COVID-19, when compared to moderate cases (771.7 mm3 (Q1 = 49.8 mm3, Q3 = 3065.5 mm3) vs. 0 mm3 (Q1 = 0 mm3, Q3 = 57.3 mm3)). Within multivariate regression analysis, including AWC, patient age and sex, as well as a cardiovascular comorbidity score, the volume of AWC was the only significant regressor for severe COVID-19 (p = 0.004). For AWC > 3000 mm3, the logistic regression predicts risk for a severe progression of 0.78. If there are no visually detectable AWC risk for severe progression is 0.13, only.
CONCLUSION
AWC seems to be an independent biomarker for the prediction of severe progression and intensive care treatment of COVID-19 already at the time of patient admission to the hospital; verification in a larger multi-center, multi-vendor study is desired.
Identifiants
pubmed: 33362199
doi: 10.1371/journal.pone.0244267
pii: PONE-D-20-23872
pmc: PMC7757863
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244267Déclaration de conflit d'intérêts
David Maintz has received speaker’s honoraria from Philips Healthcare, unrelated to the presented work. David Zopfs has received exemption from clinical duties as part of a research agreement between Philips Healthcare and University Hospital Cologne, unrelated to this project. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1463-1465
pubmed: 32771919
Am J Cardiol. 1990 Nov 1;66(15):1060-4
pubmed: 2220632
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
Eur Radiol. 2020 Oct;30(10):5446-5454
pubmed: 32367418
Circulation. 2020 Jul 7;142(1):68-78
pubmed: 32293910
FEBS J. 2020 Sep;287(17):3651-3655
pubmed: 32189428
Med Phys. 2010 Feb;37(2):714-23
pubmed: 20229881
Circ J. 2004 Jun;68(6):538-41
pubmed: 15170088
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
JACC Cardiovasc Imaging. 2016 Dec;9(12):1417-1419
pubmed: 27931526
Eur J Med Res. 2017 Nov 16;22(1):47
pubmed: 29145895
Infez Med. 2020 Ahead of print Jun 1;28(2):153-165
pubmed: 32275257
Recenti Prog Med. 2020 Apr;111(4):238-252
pubmed: 32319446
Acta Neurochir (Wien). 2020 Jun;162(6):1227-1228
pubmed: 32291593
Radiology. 2020 Apr;295(1):66-79
pubmed: 32043947
Am Heart J. 2008 Apr;155(4):765-71
pubmed: 18371491
Anesthesiology. 2020 Jun;132(6):1333-1338
pubmed: 32195704
Intensive Care Med. 2020 Aug;46(8):1648-1650
pubmed: 32468085
Tob Induc Dis. 2020 Jul 03;18:58
pubmed: 32641924
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 1986 Nov 15;2(8516):1120-2
pubmed: 2877272
Eur Heart J Cardiovasc Imaging. 2018 Dec 1;19(12):1362-1371
pubmed: 29432592
Am J Cardiol. 1991 Jul 1;68(1):1-6
pubmed: 2058541
Radiology. 2020 Sep;296(3):E145-E155
pubmed: 32301646
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Lancet Respir Med. 2020 Jul;8(7):664-665
pubmed: 32464099
Int J Antimicrob Agents. 2020 May;55(5):105955
pubmed: 32234468
Circulation. 1995 Sep 1;92(5):1355-74
pubmed: 7648691
Geroscience. 2020 Apr;42(2):505-514
pubmed: 32274617
IEEE Trans Med Imaging. 2018 Feb;37(2):615-625
pubmed: 29408789
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Eur J Prev Cardiol. 2018 Nov;25(16):1756-1764
pubmed: 30095278
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1926-1932
pubmed: 29954753
Chest. 2020 Jul;158(1):106-116
pubmed: 32275978